Key Takeaways

• FDA-approved weight loss medications range from older options like orlistat (Xenical, approved in 1999) to newer injections like tirzepatide (Zepbound, approved in 2023).
• Most current FDA-approved weight loss meds are intended for long-term use, while phentermine is a short-term option (typically up to 12 weeks).
• Prescription eligibility often starts at BMI 30+, or BMI 27 to 29.9 with at least one weight-related condition (like type 2 diabetes, high blood pressure, or sleep apnea).

We’ve seen how FDA approved weight loss meds have evolved into a cornerstone of obesity management for eligible adults. In this complete guide, we’ll explore the history of these medications, compare long-term and short-term options, unpack BMI criteria for prescription, trace approvals from fen-phen to Zepbound, highlight common off-label uses, explain label warnings and black box issues, and offer practical tips on talking to your doctor about them.

History of FDA approvals for weight loss drugs

Our journey begins in the late 1990s and accelerates over the next three decades as research revealed new pharmacologic targets for obesity.

Early era: fen-phen and orlistat

• 1996: The combination of fenfluramine and phentermine, known as fen-phen, is withdrawn due to heart valve damage.
• 1999: Orlistat (Xenical) earns FDA approval, reducing fat absorption by about 30 percent and paving the way for non-stimulant treatments.

Modern approvals: 2012 to present

Between 2012 and 2022, five major weight loss medications received FDA approval, all demonstrating meaningful reductions in body weight PubMed:

• 2012: Phentermine/topiramate (Qsymia) for combined appetite suppression and satiety enhancement
• 2014: Naltrexone/bupropion (Contrave) targeting reward pathways
• 2014: Liraglutide (Saxenda), a daily GLP-1 receptor agonist
• 2021: Semaglutide (Wegovy), a weekly GLP-1 injection with superior efficacy
• 2023: Tirzepatide (Zepbound), a dual GIP and GLP-1 agonist showing up to 22.5 percent weight loss at 72 weeks Obesity Medicine Association

Each of these milestones reflects growing confidence in obesity pharmacotherapy as part of a comprehensive lifestyle program.

List of long-term vs short-term approved medications

Understanding which drugs are intended for long-term management versus short-term use helps us set realistic expectations and monitor safety.

Medication	Brand (examples)	Approval type	Intended duration	Mechanism
Phentermine	Adipex-P, Lomaira	Short-term	Up to 12 weeks	Sympathomimetic appetite suppressant
Orlistat	Xenical, Alli	Long-term	Indefinite with diet	Lipase inhibitor
Phentermine/topiramate	Qsymia	Long-term	Ongoing	Appetite and satiety modulation
Naltrexone/bupropion	Contrave	Long-term	Ongoing	Reward pathway regulation
Liraglutide	Saxenda	Long-term	Ongoing	GLP-1 receptor agonist
Semaglutide	Wegovy	Long-term	Ongoing	GLP-1 receptor agonist
Tirzepatide	Zepbound	Long-term	Ongoing	Dual GIP and GLP-1 agonist

Short-term phentermine remains the only stimulant approved for limited use, while the rest address metabolism, satiety, or reward circuits over months to years. For detailed dosing, see our guide to names of weight loss meds.

Understanding BMI criteria for prescription eligibility

BMI thresholds ensure we prescribe weight loss medications to those most likely to benefit and least likely to encounter risks.

Eligibility criteria

• Adults with BMI ≥30
• Adults with BMI 27–29.9 plus at least one weight-related condition (type 2 diabetes, high blood pressure, sleep apnea)
• Children aged 12 and older (for semaglutide or liraglutide) with BMI ≥95th percentile
• Children aged 6 and older (for setmelanotide) with rare genetic obesity syndromes

According to Dr. Neil Zemmel, individuals who are pregnant, breastfeeding, or have uncontrolled thyroid disease or certain cardiovascular conditions generally should not start these medications Dr. Neil Zemmel. Always confirm eligibility with a healthcare provider before beginning treatment.

Timeline of drug approval: from fen-phen to Zepbound

A clear chronology helps us appreciate how safety and efficacy data shaped each approval.

1. 1996: Fen-phen withdrawn due to heart valve risks
2. 1999: Orlistat (Xenical) approved, marking the first fat-absorption blocker
3. 2012: Qsymia (phentermine/topiramate) enters the market as the first combination therapy
4. 2014: Contrave (naltrexone/bupropion) and Saxenda (liraglutide) expand options beyond stimulants
5. 2021: Wegovy (semaglutide) gains approval for superior weight loss over prior agents
6. 2023: Zepbound (tirzepatide) achieves up to 22.5 percent average body weight reduction in SURMOUNT-1 Obesity Medicine Association

This timeline illustrates steady progress from short-term appetite suppressants to powerful injectable therapies that target metabolic pathways.

Off-label uses of FDA-approved weight loss meds

Many of these medications affect neural and hormonal processes beyond appetite, leading clinicians to explore off-label applications.

• Bupropion (in naltrexone/bupropion) for smoking cessation and depression
• Phentermine/topiramate in migraine prevention and binge eating disorder
• Liraglutide for nonalcoholic fatty liver disease under investigation
• Semaglutide for prediabetes management in high-risk individuals
• Tirzepatide for glucose control in type 2 diabetes (Mounjaro brand)

Off-label prescribing should be guided by peer-reviewed evidence and close monitoring. Always discuss potential uses and risks thoroughly with your healthcare team.

FDA label warnings and black box issues explained

Understanding label warnings ensures we weigh benefits against potential harms.

Black box warnings

• Naltrexone/bupropion carries a suicide risk warning related to the bupropion component
• GLP-1 agonists may increase risk of pancreatitis and gallbladder disease JAMA

Common label cautions

• Gastrointestinal symptoms (nausea, vomiting, diarrhea) with GLP-1 drugs, often abating over time Harvard Health Publishing
• Elevated heart rate or blood pressure with stimulants and combinations
• Hypoglycemia risk when used with insulin or sulfonylureas

The FDA also warns against unlicensed compounded versions of semaglutide and tirzepatide due to reports of adverse events. Always verify prescriptions are dispensed by licensed pharmacies.

How to talk to your doctor about FDA-approved options

A confident, informed conversation helps us choose the right path for sustainable weight loss.

1. Gather your medical history

• List current medications, past weight loss attempts, and any comorbidities

1. Define your goals

• Weight targets, waist circumference, activity level improvements

1. Discuss eligibility and risks

• Ask about BMI criteria, side effects (weight loss meds side effects), and label warnings

1. Explore cost and coverage

• Inquire about insurance benefits, out-of-pocket costs, and patient assistance programs (cost of weight loss meds)

1. Consider alternatives and updates

• Review new formulations (new weight loss meds) and top choices (best weight loss meds)

1. Plan follow-up

• Schedule regular check-ins to monitor progress, labs, and any side effects

By coming prepared, we can collaborate with our provider to select the most appropriate fda approved weight loss meds and integrate them safely into a broader lifestyle plan.

Key takeaways:

• FDA approvals span from orlistat in 1999 to tirzepatide in 2023
• Long-term agents outnumber short-term stimulants
• BMI thresholds and medical history guide eligibility
• Label warnings underscore the need for medical supervision
• Open communication ensures we choose safe, effective therapies

Use this guide to inform your next steps, then schedule a consultation to see which option aligns with your health profile and weight loss goals.

Frequently Asked Questions About FDA-Approved Weight Loss Medications